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Isorhapontigenin is a polyphenolic compound found in Chinese herbs and grapes. It is a 
methoxylated analogue of a stilbenoid, resveratrol, which is well-known for its various beneficial 
effects including anti-platelet activity. Isorhapontigenin possesses greater oral bioavailability than 
resveratrol and has also been identified to possess anti-cancer and anti-inflammatory properties. 
However, its effects on platelet function have not been reported previously. In this study, we report 
the effects of isorhapontigenin on the modulation of platelet function. Isorhapontigenin was found 
to selectively inhibit ADP-induced platelet aggregation with an IC50 of 1.85µM although it displayed 
marginal inhibition on platelet aggregation induced by other platelet agonists at 100µM. However, 
resveratrol exhibited weaker inhibition on ADP-induced platelet aggregation (IC50>100µM) but 
inhibited collagen induced platelet aggregation at 50µM and 100µM. Isorhapontigenin also 
inhibited integrin αIIbβ3 mediated inside-out and outside-in signalling and dense granule secretion 
in ADP-induced platelet activation but interestingly, no effect was observed on α-granule secretion. 
Isorhapontigenin did not exert any cytotoxicity on platelets at the concentrations of up to 100µM. 
Furthermore, it did not affect haemostasis in mice at the IC50 concentration (1.85µM). In addition, 
the mechanistic studies demonstrated that isorhapontigenin increased cAMP levels and VASP 
phosphorylation at Ser157 and decreased Akt phosphorylation. This suggests that 
isorhapontigenin may interfere with cAMP and PI3K signalling pathways that are associated with 
the P2Y12 receptor. Molecular docking studies emphasised that isorhapontigenin has greater 
binding affinity to P2Y12 receptor than resveratrol. Our results demonstrate that isorhapontigenin 
has selective inhibitory effects on ADP-stimulated platelet activation possibly via P2Y12 receptor. 
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1. Introduction  
Platelets are small circulating blood cells that maintain haemostasis upon vascular injury, 
however, their unnecessary activation leads to thrombosis (George, 2000; Ruggeri, 2002). 
Thrombosis is the most common pathology that underpins major cardiovascular diseases such as 
acute coronary syndrome (ischemic heart disease) and stroke (Raskob et al., 2014). Although, 
anti-platelet drugs such as aspirin and clopidogrel are being used for the treatment of thrombotic 
complications, there is a great unmet clinical need for developing more effective and safer anti-
platelet agents due to their severe side effects (Koupenova et al., 2017). Natural products, 
especially phytochemicals have always been an important source of new chemical entities (NCEs) 
in drug discovery (Cragg and Newman, 2013). Polyphenols such as stilbenoid and flavonoid 
classes of bioactive compounds are considered as promising molecular templates for drug design 
(Cuccioloni et al., 2009; Wright et al., 2013). Flavonoids such as quercetin (Hubbard et al., 2003), 
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chrysin (Liu et al., 2016), tangeretin (Vaiyapuri et al., 2013) and nobiletin (Vaiyapuri et al., 2015a) 
have been reported to modulate platelet function through distinct mechanisms. Resveratrol (Res, 
Fig 1Ai) [trans-3′,4′,5-trihydroxystilbene], a phytochemical that primarily found in grapes and its 
products such as red wine is known to exert various pharmacological activities (Berman et al., 
2017; Kuršvietienė et al., 2016)  including cardioprotective (Das and Das, 2010) and anti-platelet 
activities (Olas et al., 2002; Olas and Wachowicz, 2005). However, the therapeutic potential of 
resveratrol is greatly hampered by its low oral bioavailability (<1%) due to rapid metabolism in the 
liver and intestine (Sergides et al., 2016). Isorhapontigenin (ISO, Fig 1Aii), a new derivative of 
stilbene is a methoxylated analogue of resveratrol isolated from a Chinese herb, Gnetum 
Cleistostachyum (Huang et al., 2002) and is also reported to be present in grapes (Fernández-
Marín et al., 2012). Isorhapontigenin has been demonstrated to exhibit anti-cancer (Fang et al., 
2012), anti-oxidant (Lu et al., 2017) and anti-inflammatory (Yeo et al., 2017) effects. Notably, 
isorhapontigenin was found to be more orally bioavailable than resveratrol, thus possesses more 
favourable pharmacokinetic properties compared to resveratrol (Yeo et al., 2017). Furthermore, 
studies have shown that isorhapontigenin displays protective effects against cardiac hypertrophy 
induced by angiotensin II both in vitro and in vivo (Li et al., 2005) and it is also reported to have 
cardioprotective effects against isoproterenol-induced myocardial infarction in rats (Abbas, 2016). 
However, its effects on the modulation of platelet function have not been established previously. 
So, owing to the structural similarity of isorhapontigenin and resveratrol, here, we report the effects 
of isorhapontigenin on the modulation of platelet function in comparison to its analogue, 
resveratrol. 
2. Materials and Methods 
2.1. Human platelet preparation 
Blood was obtained from healthy, aspirin-free individuals with informed consent in 
accordance with the methods approved by the University of Reading Research Ethics Committee 
(Approval number: UREC 17/17). All the experiments were performed in accordance with the 
relevant institutional and national guidelines and regulations and this study conform to the 
principles outlined in the Declaration of Helsinki. The preparation of human platelets was carried 
out using standard protocols as described previously (Ravishankar et al., 2018, 2017; Vaiyapuri et 
al., 2015b, 2013). Briefly, human blood was collected via venepuncture into vacutainers containing 
3.2% (w/v) citrate and the blood samples were centrifuged at 102 g for 20 min at 20 °C to separate 
the platelet-rich plasma (PRP), which was used in aggregation and flow cytometry assays.  
Isolated platelets were prepared by mixing 50 ml of blood with 7.5 ml of ACD (acid citrate dextrose) 
(20 g/L glucose, 25 g/L sodium citrate and 15 g/L citric acid) and this was centrifuged at 102 g for 
20 min at 20 °C. The PRP was carefully separated and mixed with 3 ml of ACD and PGI2 (125 
ng/ml) was added and then centrifuged at 1413 g for 10 min at 20 °C. The platelet pellet was 
washed by resuspending in modified Tyrodes-HEPES buffer (25 ml) [2.9 mM KCl, 134 mM NaCl, 
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0.34 mM Na2HPO4.12H2O, 1 mM MgCl2, 12 mM NaHCO3, 20 mM HEPES, pH 7.3] in the presence 
of PGI2 (125 µg/ml) and centrifuging at 1413 g for 10 min. The obtained platelet pellet was finally 
resuspended in modified Tyrodes-HEPES buffer at a density of 4 × 108 cells/ml and rested for 30 
min before use.  
Isorhapontigenin and resveratrol (Sigma Aldrich, UK; >95% Purity) were dissolved in 
DMSO (100%) at 10 mg/ml stock concentration. This was further diluted to the desirable 
concentration for assays and the final concentration of DMSO in platelets was maintained at 0.1% 
(v/v), which did not affect platelet function. A DMSO vehicle control at a concentration of 0.1% (v/v) 
was included in all the experiments.   
2.2. Platelet aggregation and dense granule secretion  
Platelet aggregation assays were performed by optical aggregometry (Chrono-Log, USA) in 
the presence or absence of various concentrations of isorhapontigenin or resveratrol along with a 
vehicle control. The different concentrations of isorhapontigenin, resveratrol or a vehicle control 
[0.1% (v/v) DMSO] (5 μl) were added to 445 μl of PRP or isolated platelets and incubated for 5 min 
at 37 °C. The samples were then activated with 50 μl ADP (5 µM) (Sigma-Aldrich, UK), collagen (1 
µg/ml) (Nycomed, Austria), cross-linked collagen-related peptide (0.5 µg/ml) [CRP-XL, from 
Professor Richard Farndale (University of Cambridge)] or U46619 (1 µM) (Tocris, UK) and the 
platelet aggregation was monitored for 5 min.  
The dense granule secretion in platelets was determined by measuring ATP release using 
the luciferin-luciferase reagent by lumi-aggregometry (Chrono-Log, USA). Briefly, PRP (395 μl) 
was incubated with Chrono-Lume reagent (50 μl) at 37 °C for 2 min then this was further incubated 
for 5 min with 5 μl of various concentrations of isorhapontigenin or resveratrol and the platelets 
were activated with 50 μl of ADP (5 µM). The incubation with isorhapontigenin or resveratrol itself 
has not affected the luciferase activity (Fig S1). 
2.3. Immunoblotting analysis 
 The platelet lysates for immunoblotting experiments were obtained by treating human 
isolated platelets with different concentrations of isorhapontigenin and a vehicle control [0.1% (v/v) 
DMSO], followed by the addition of an agonist to trigger platelet activation using optical 
aggregometer. After 5 min, the activation was stopped by adding lysis buffer (6X Reducing 
sample-treatment buffer: 12% (w/v) SDS, 30% (v/v) β-Mercaptoethanol, 30% (v/v) Glycerol and 
30% (v/v) Stacking gel buffer). 
SDS-PAGE and immunoblotting analyses were carried out using standard protocols as 
described previously (Moraes et al., 2016; Vaiyapuri et al., 2013). The phospho-specific primary 
antibodies for human AKT pS473, and VASP pS157 were obtained from Cell Signalling 
technology, UK and rabbit anti-human 14-3-3ζ antibody (Santa Cruz Biotechnology, USA) was 
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used to detect 14-3-3ζ protein as a loading control. The Cy5-conjugated goat anti-rabbit IgG 
secondary antibody (Life technologies, UK) was used for detection. 
2.4. Flow cytometry-based assays  
The levels of fibrinogen binding and P-selectin exposure were measured by flow cytometry 
(Accuri C6, BD Biosciences, UK). The platelets (PRP) were treated with different concentrations of 
isorhapontigenin or resveratrol or a vehicle control for 5 min prior to activation with agonists such 
as ADP (5 µM), CRP-XL (0.5 µg/ml) or U46619 (1 µM) for further 20 min in the presence of FITC-
conjugated anti-human fibrinogen antibodies (Dako, UK) and PECy5-conjugated CD62P 
antibodies (BD Biosciences, UK). The platelets were fixed using 0.2% (v/v) formyl saline and then 
analysed by flow cytometry by collecting 5000 events within a gated region for platelets. The 
median fluorescence intensity was used to assess the level of fibrinogen binding (a marker for 
inside-out signalling to integrin αIIbβ3) and P-selectin exposure (a marker for α-granule secretion) 
on the platelet surface. The level of fibrinogen binding and P-selectin exposure in the treated 
samples was calculated by taking the level of median fluorescence intensity obtained with the 
vehicle control as 100%. 
2.5. cAMP assay 
 The cAMP levels were determined using a cAMP ELISA kit (Cambridge Bioscience, UK). 
Human isolated platelets were pre-incubated (for 5 min) with a vehicle [0.1% (v/v) DMSO] or 
different concentrations of isorhapontigenin (3.125-100 μM) followed by activation with ADP (5 µM) 
and the platelets treated with EGTA (1 mM) were considered as a control for maximum cAMP 
levels. These platelets were lysed with 0.1 M HCl and the levels of cAMP were determined 
according to the manufacturer’s protocol. 
2.6. Platelet spreading 
Isolated platelets (2x107 cells/ml) treated (for 5 min) with a vehicle control [0.1% (v/v) 
DMSO] or isorhapontigenin (3.125 and 6.25 μM) were allowed to spread on fibrinogen- (100 μg/ml) 
coated cover-glasses for 45 min. The unbound platelets were removed by washing with phosphate 
buffered saline (PBS) and the adhered platelets were fixed using 2% (v/v) formaldehyde in PBS. 
Platelets were permeabilised with 0.1% (v/v) Triton-X in PBS (10 min) and then stained with Alexa 
Fluor 488 conjugated phalloidin for 30 min. Images were obtained using a Nikon A1-R Confocal 
microscope and the analysed using ImageJ (NIH, USA) to calculate the number of adhered and 
fully spread platelets. 
2.7. Tail bleeding assay 
The tail bleeding assay performed in this study was approved by the University of Reading 
Research Ethics Committee and the British Home Office. In brief, C57BL/6 mice [9 weeks old (6 
per group; both males and females) from Envigo, UK] were anaesthetised via intraperitoneal route 
using ketamine (80 mg/kg) and xylazine (5 mg/kg) 20 min prior to the experiment and placed on a 
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heated pad at 37 °C. A vehicle control [0.1% (v/v) DMSO] or isorhapontigenin (6.25 µM and 1.85 
µM- final concentrations were calculated based on the mouse weight and approximate blood 
volume) was injected via femoral artery and after 5 min of incubation, 3 mm of tail tip was 
dissected using a scalpel blade and the tail tip was placed in sterile PBS. The time taken to 
cessation of bleeding was measured up to 20 min when the assay was terminated.   
2.8. Statistical analysis 
Most of the data in this study are represented as mean ± S.E.M  in a bar graph format as 
the data were normalised to the control for each donor. However, the data for tail bleeding assay is 
presented as a dot plot. All the statistical analyses in this study were carried out using GraphPad 
Prism 7 software (GraphPad Software Inc., USA). The statistical significance between the control 
and isorhapontigenin or resveratrol treated samples was determined using one-way ANOVA 
followed by Bonferroni post-hoc analysis for the normalised data obtained from aggregation and 
flow cytometry assays. The data obtained from tail bleeding assay were analysed using non-
parametric Kruskal-Wallis test followed by Bonferroni post-hoc analysis. The IC50 values were 
calculated by log transforming the concentration values followed by curve fitting using non-linear 
regression using four parameter model [Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))] 
in GraphPad Prism 7 software. 
The methods for the lactate dehydrogenase assay and molecular docking analysis are 
provided in the supplementary information.  
 
3. Results   
3.1. Isorhapontigenin inhibits platelet aggregation differently from resveratrol 
  Resveratrol has been reported to inhibit platelet aggregation induced by various agonists 
(Wang et al., 2002; Wu et al., 2007). Thus, to characterise the effects of isorhapontigenin on the 
modulation of platelet function in comparison to resveratrol, platelet aggregation assays were 
carried out using various agonists by optical aggregometry. Human PRP was incubated with a 
vehicle control [0.1% (v/v) DMSO] or different concentrations (3.125-100 µM) of isorhapontigenin 
or resveratrol for 5 min prior to activation with diverse agonists such as ADP (5 µM; acts via P2Y1 
and P2Y12 receptors), collagen (1 µg/ml; acts via GPVI and α2β1 receptors), CRP-XL (0.5 µg/ml; 
acts via GPVI receptor) and U46619, a TxA2 analogue (1 µM; acts via thromboxane (TP) receptor). 
Isorhapontigenin was found to significantly inhibit ADP-induced platelet aggregation at all the 
concentrations tested (~50% inhibition) (Fig 1B). However, it only marginally inhibited (<10%) both 
collagen (Fig 1C) and CRP-XL-induced platelet aggregation only at 100 µM (Fig 1D), and it 
displayed no inhibitory effect on U46619- (Fig 1E) induced platelet activation. Furthermore, the IC50 
concentration of isorhapontigenin for ADP-induced aggregation was determined to be 1.85 ± 0.56 
µM (Fig 1F). Notably, the inhibition effects of isorhapontigenin (Fig 1B and 1F) are not dose-
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dependent under the current experimental settings used in this study. However, further studies will 
be performed to explain this lack of dose-dependent effects with isorhapontigenin in platelet 
aggregation.  
In contrast, resveratrol inhibited ADP-induced platelet activation only at 50 and 100 µM (Fig 
2A). It displayed complete inhibition of collagen-induced platelet activation at 100 µM (Fig 2B) but 
only moderately inhibited CRP-XL (Fig 2C) and U46619 (Fig 2D)-induced platelet activation at 100 
µM. These results suggest that isorhapontigenin inhibits ADP-induced platelet activation at 
concentrations of less than 3 µM while, resveratrol exhibits inhibitory effects only at higher 
concentrations. Thus, isorhapontigenin exhibits a different inhibitory profile to resveratrol and it 
appears to be a selective and effective modulator of ADP-stimulated platelet aggregation.  
 Furthermore, the effects of isorhapontigenin and resveratrol on isolated platelets (without 
plasma proteins) were assessed. Isorhapontigenin showed significant inhibition of collagen-
induced aggregation only at 50 and 100 µM (Fig 3A) and U46619-induced aggregation at 100 µM 
(Fig 3B). However, resveratrol inhibited collagen-induced aggregation at all the concentrations 
tested (Fig 3C) and U46619-induced aggregation at only 50 and 100 µM (Fig 3D). This again 
suggests that isorhapontigenin exhibits different inhibitory profile to resveratrol. 
3.2. Inside-out signalling to integrin αIIbβ3 is affected by isorhapontigenin 
 The platelet activation initiated by diverse agonists leads to the activation of integrin αIIbβ3, 
a highly abundant platelet surface receptor, which plays a critical role in platelet aggregation 
(Shattil et al., 1998). The inside-out signalling to integrin αIIbβ3 transforms this receptor from a 
low-affinity, resting state to a high affinity state for fibrinogen and von Willebrand factor (vWF) 
binding that consequently leads to platelet aggregation (Estevez and Du, 2017). As 
isorhapontigenin and resveratrol inhibited platelet aggregation induced by various agonists, their 
effects on the inside-out signalling to integrin αIIbβ3 upon agonist-induced platelet activation were 
assessed. Human PRP was treated with a vehicle control [0.1% (v/v) DMSO] or different 
concentrations (3.125-100 µM) of isorhapontigenin or resveratrol for 5 min followed by incubation 
with various agonists such as ADP (5 µM), CRP-XL (0.5 µg/ml) and U46619 (1 µM) and the level 
of fibrinogen binding was measured by flow cytometry. Consistent with the platelet aggregation 
data, isorhapontigenin reduced the level of fibrinogen binding in platelets only when stimulated with 
ADP but at concentrations of 25 µM and above (Fig 4A). In addition, isorhapontigenin did not affect 
U46619 (Fig 4B) and CRP-XL (Fig 4C)- induced activation. Nevertheless, resveratrol did not affect 
the fibrinogen binding upon stimulation with any of the agonists (Fig 4D-F). This suggests that 
isorhapontigenin affects inside out signalling to integrin αIIbβ3 in platelets specifically upon 
stimulation with ADP. These results highlight that isorhapontigenin may be more potent than its 




3.3. Isorhapontigenin selectively inhibits dense granule secretion in platelets  
Platelets undergo degranulation during their activation and release several effector 
molecules from their granules which amplify platelet activation and thrombus formation 
(Flaumenhaft, 2003; White and Estensen, 1972). Platelets contain three major types of secretory 
granules namely, α-granules, dense granules and lysosomes. α-granules contain mainly proteins 
such as fibrinogen, vWF and P-selectin whereas dense granules contain small organic molecules 
such as ADP, ATP and serotonin (Whiteheart, 2011). To assess the effects of isorhapontigenin 
and resveratrol on α-granule secretion, human PRP was treated with a vehicle control [0.1% (v/v) 
DMSO] or different concentrations (3.125-100 µM) of isorhapontigenin or resveratrol for 5 min 
followed by incubation with agonists such as ADP (5 µM), CRP-XL (0.5 µg/ml) and U46619 (1 µM) 
for 20 min and the level of P-selectin exposure (as a marker for α-granule secretion) was 
measured using flow cytometry. Interestingly, isorhapontigenin did not show any inhibitory effects 
on the P-selectin exposure upon stimulation with any of the agonists tested (Fig 4G-I). Similarly, 
resveratrol also did not inhibit P-selectin exposure on platelets triggered with ADP (Fig 4J) and 
U46619 (Fig 4K). However, resveratrol moderately inhibited the P-selectin exposure at higher 
concentrations of 50 µM and 100 µM when platelets were stimulated with CRP-XL (Fig 4L). 
Furthermore, the effects of isorhapontigenin and resveratrol on dense granule secretion 
were assessed in human PRP.  The level of ATP secretion (a marker for dense granule secretion) 
was measured in platelets in the presence and absence of different concentrations of 
isorhapontigenin or resveratrol upon activation with 5 μM ADP using a luciferin-luciferase 
luminescence assay. Isorhapontigenin significantly inhibited dense granule secretion at all the 
concentrations tested (3.125-100 μM) with 100% inhibition observed at 100 μM (Fig 5A). However, 
resveratrol showed significant inhibition on dense granule secretion at concentrations of 12.5 μM 
and above (Fig 5B). These data demonstrate that isorhapontigenin primarily affects dense granule 
secretion but not α-granule secretion in platelets and also, the inhibitory potency of 
isorhapontigenin is greater than resveratrol. 
3.4. Isorhapontigenin inhibits platelet spreading 
 The outside-in signalling triggered by integrin αIIbβ3 in response to fibrinogen binding leads 
to platelet spreading (Li et al., 2010) which initiates clot retraction and wound healing. To further 
evaluate the effects of isorhapontigenin on integrin αIIbβ3-mediated outside-in signalling, platelet 
spreading on immobilised fibrinogen in the presence and absence of isorhapontigenin was carried 
out. As shown in Fig 6, platelets treated with isorhapontigenin (3.125 and 6.25 μM) were unable to 
spread in a similar manner to the untreated control. This data suggests that isorhapontigenin is 




3.5. Effect of isorhapontigenin on haemostasis in mice  
 Haemostasis is a normal physiological response of the body for prevention of bleeding 
upon vascular injury (Batty and Smith, 2010). A tail bleeding assay in mice was performed to 
investigate the effect of isorhapontigenin on the modulation of haemostasis under physiological 
conditions. A vehicle control or isorhapontigenin [final concentration of 1.85 μM (IC50 
concentration) or 6.25 μM] was infused into anaesthetised mice through femoral arteries. After five 
min of incubation, 3 mm of tail tip was dissected, and the bleeding time was recorded. The mean 
bleeding time in the isorhapontigenin (1.85 μM)-administered group was about 384 seconds, which 
was not significantly different from the vehicle-treated group (Average: 347 seconds) (Fig 7A). 
However, a significant extension of bleeding time was observed when 6.25 μM of isorhapontigenin 
was used. These data illustrate that isorhapontigenin does not affect haemostasis at its IC50 
concentration of 1.85 μM, hence, this may be safe and may not cause bleeding complications at 
this concentration under in vivo physiological settings. 
3.6. Isorhapontigenin does not exert cytotoxic effects in platelets 
 In order to assess whether the observed effects of isorhapontigenin are due to its toxicity 
against platelets, LDH cytotoxicity assay, which is one of the common and sensitive assay (Kumar 
et al., 2018; Smith et al., 2011) was performed. This was carried out using human PRP in the 
presence of isorhapontigenin at the concentrations used in this study, along with a vehicle and 
positive controls. As shown in Fig 7B, isorhapontigenin does not possess any cytotoxic effects on 
platelets at all the concentrations tested in this study. This indicates that the inhibitory properties 
observed for isorhapontigenin are due to its pharmacological effects and not due to its adverse 
toxic effects in platelets.  
3.7 Isorhapontigenin affects the phosphorylation of vasodilator-stimulated 
phosphoprotein (VASP), Akt and cAMP in platelets 
 Isorhapontigenin has consistently displayed selective inhibition of ADP-stimulated platelet 
activation. ADP acts via purinergic receptors P2Y1 and P2Y12 in platelets to initiate/promote their 
activation. Specifically, the interaction of ADP with P2Y12 receptor promotes platelet aggregation 
(Hechler and Gachet, 2011; Wijeyeratne and Heptinstall, 2011). As isorhapontigenin inhibited 
fibrinogen binding and aggregation in platelets upon stimulation with ADP, we hypothesised that 
isorhapontigenin predominantly mediates its activity via P2Y12 receptor. Hence, we explored the 
effects of isorhapontigenin on the signalling pathways relating to P2Y12 receptor by immunoblotting 
analysis. Binding of ADP to the P2Y12 receptor inhibits adenylate cyclase which reduces the levels 
of cyclic AMP (cAMP) allowing platelet aggregation. To assess the effect of isorhapontigenin on 
cAMP-mediated signalling, the level of phosphorylation of VASP; a substrate for cAMP protein 
kinase (Butt et al., 1994; Wentworth et al., 2006) at position S157 was analysed. As shown in Fig 
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7C, isorhapontigenin has increased the phosphorylation of VASP at S157 in a concentration-
dependent manner. Furthermore, the effect of isorhapontigenin on Akt phosphorylation at S473 
was analysed to determine the impact of isorhapontigenin on PI3K-mediated signalling. Indeed, 
isorhapontigenin was found to inhibit Akt phosphorylation (Fig 7D). These results imply that the 
inhibitory effects of isorhapontigenin may be due to its interference with the cAMP and PI3K-
mediated signalling pathways that are associated with the P2Y12 receptor in platelets (Hechler and 
Gachet, 2011; Kim and Kunapuli, 2011).  
In order to further investigate the effect of isorhapontigenin on the cAMP signalling, which is 
an important mediator of platelet activation (Noe et al., 2010), the intracellular cAMP levels in the 
presence and the absence of isorhapontigenin was determined using a cAMP ELISA kit. The 
results revealed that the platelets treated with isorhapontigenin prior to the activation by the 
agonist (ADP-5 μM) showed an increased level of cAMP in a concentration- dependent manner 
when compared to the platelets treated with agonist alone (Fig 7E). This result further emphasises 
that isorhapontigenin may interfere with the cAMP-mediated signalling pathways. 
3.8. Isorhapontigenin has greater binding affinity towards P2Y12 receptor than 
resveratrol 
The above results emphasise that isorhapontigenin exerts greater inhibitory effects than 
resveratrol on ADP-stimulated platelet activation, which is predominantly mediated via the P2Y12 
receptor. Hence, the potential molecular interactions between isorhapontigenin or resveratrol and 
the P2Y12 receptor were elucidated by molecular docking analysis. For this, the molecules 
[isorhapontigenin, resveratrol and clopidogrel (CLO), a P2Y12 inhibitor (Bates et al., 2011; 
Wallentin, 2009; Wijeyeratne and Heptinstall, 2011) for comparison] were docked sequentially into 
the binding site of the X-ray crystallographic structure of P2Y12 receptor (PDB-4PXZ) (J. Zhang et 
al., 2014) using SYBYL-X 2.1. The docking procedure was first validated by re-docking the 
extracted co-crystallised ligand of the P2Y12 receptor [2-methylthio-adenosine-5'-diphosphate 
(2MeSADP)] into the prepared protein to be used for docking. The RMSD between the docked 
conformation generated by the program and the native co-crystallized ligand conformation was 
found to be 0.248 Å. Since, the RMSD value was well within the 2 Å grid spacing used for docking, 
it indicated that the docking procedure to be used was reliable and valid. Moreover, the 
interactions between the docked ligand and the receptor mimicked those observed in the crystal 
structure of the same. 
The results of ligand-directed docking into the ADP-binding site of P2Y12 receptor are 
summarised in Table 1 in decreasing order of the ligand binding affinities, as determined by their 
docking scores. The binding modes of isorhapontigenin, resveratrol and clopidogrel with P2Y12 
receptor are depicted in Fig 8. Isorhapontigenin has shown potential interactions with the key 
residues, Phe-106, Gln-263, Thr-163, Cys-97 and Cys-197 of P2Y12 receptor through hydrogen 
bonding (Fig 8C), whereas resveratrol has interacted only with Gln-263, Thr-163 and Cys-97 (Fig 
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8D) of P2Y12 receptor through hydrogen bonds. Interestingly, the interactions of isorhapontigenin 
and resveratrol with the P2Y12 receptor were found to be distinct from clopidogrel, which interacted 
with Arg-256 and Try-105 (Fig 8D) residues of the ligand binding pocket of P2Y12 receptor. The 
docking scores suggest that isorhapontigenin (6.68) has a higher binding affinity towards P2Y12 
receptor than resveratrol (5.97) and clopidogrel (5.95). These results indicate that the superior 
inhibitory effects of isorhapontigenin on ADP-stimulated platelet activation in comparison to 
resveratrol could be due to its greater interactions with the P2Y12 receptor. 
 
4. Discussion  
Polyphenols such as resveratrol are well acknowledged for their cardioprotective [38] and 
anti-platelet activities (Olas et al., 2002). The recently identified methoxylated analogue, 
isorhapontigenin has also been found to be bioactive. Similar to resveratrol, isorhapontigenin is a 
potent antioxidant and it decreases ROS (Reactive Oxygen Species) generation (Lu et al., 2017; 
Wang et al., 2001). Isorhapontigenin also exhibits anti-cancer activities (Fang et al., 2012; Gao et 
al., 2014), cardioprotective properties and attenuates cardiac hypertrophy (Li et al., 2005; Liu and 
Liu, 2004). Isorhapontigenin is attracting greater research interest due to its increased 
bioavailability (>50%) compared to resveratrol (Yeo et al., 2017). In this study, the effects of 
isorhapontigenin on platelet activity were investigated in comparison to resveratrol in human 
platelets. 
This study demonstrates that isorhapontigenin selectively inhibits ADP-induced platelet 
activation with an IC50 of around 1.85 μM. However, marginal or no inhibition was observed on 
platelet activation when stimulated with other agonists such as collagen, CRP-XL and U46619.  In 
contrast, resveratrol displayed inhibitory effects on all the agonists (ADP, collagen, CRP-XL and 
U46619)-stimulated platelet activation but only at higher concentrations (>50 μM). Notably, 
resveratrol completely abolished the platelet activation stimulated by collagen at 100 μM. These 
results are in line with the previous studies where resveratrol was found to largely inhibit platelet 
aggregation induced by collagen (1-2 μg/ml), U46619 (1 μM) and arachidonic acid (0.7 μM) but 
have a marginal inhibitory effect on ADP-induced platelet activation (5-10 μM) (Shen et al., 2007; 
Stef et al., 2006). Similar inhibitory profiles were observed for both isorhapontigenin and 
resveratrol when tested in isolated platelets upon collagen and U46619-induced activations. 
Furthermore, isorhapontigenin was able to inhibit inside-out signalling to integrin αIIbβ3 where the 
level of fibrinogen binding was significantly reduced upon stimulation with ADP although no effects 
were observed on CRP-XL and U46619 triggered activation. However, resveratrol did not show 
significant effects on the modulation of inside-out signalling to integrin αIIbβ3. This corroborates 
the results of a previous study, which reports that the inhibitory effect of resveratrol does not 
involve interaction with the integrin αIIbβ3 complex (Shen et al., 2007). The granule secretion is 
essential for platelet activation and thrombus formation (Sharda and Flaumenhaft, 2018). 
 12 
Interestingly, isorhapontigenin did not affect α-granule secretion but it markedly inhibited ATP 
release from dense granules at all the concentrations tested. However, resveratrol moderately 
inhibited α-granule secretion only upon stimulation with CRP-XL and it inhibited ATP release from 
dense granules when triggered with ADP but at a higher concentration (>25 μM) than 
isorhapontigenin. A previous study reports that resveratrol inhibits dense granule secretion 
triggered by collagen (Shen et al., 2007). These results highlight that isorhapontigenin 
preferentially affects ADP-stimulated platelet activation with greater potential than resveratrol. In 
addition, isorhapontigenin was found to significantly reduce the platelet spreading on immobilised 
fibrinogen that is mediated via integrin αIIbβ3. This suggests that isorhapontigenin may modulate 
the bidirectional signalling of integrin αIIbβ3 (both inside-out and outside-in). Remarkably, 
isorhapontigenin was found to be non-toxic to platelets at the concentrations tested here and it 
does not affect haemostasis in mice at the IC50 concentration of 1.85 μM.   
Polyphenolic compounds are known to inhibit enzymes and protein kinases that regulate 
various cellular functions (Li et al., 2012). Isorhapontigenin has been reported to inhibit NF-κB, 
MAPKs and PI3K/AKt signalling proteins in cardiomyocytes (Gao et al., 2014; Liu and Liu, 2004). 
As isorhapontigenin predominantly inhibited ADP-stimulated platelet activation, the signalling 
analyses of proteins related to P2Y12 signalling pathway suggest that isorhapontigenin has 
increased VASP phosphorylation at serine-157, which is a marker for cAMP-mediated signalling 
(Wentworth et al., 2006).  Phosphorylation of VASP at serine-157 is linked with reduced activation 
of integrin αIIbβ3 and inhibition of platelet aggregation (Horstrup et al., 1994). In addition, the 
phosphorylation of VASP negatively regulates actin nucleation and bundling properties and 
therefore reduces cytoskeletal reorganisation that is essential for platelet shape change (Aszódi et 
al., 1999). Therefore, increase in VASP phosphorylation by isorhapontigenin suggests that it may 
interfere with the cAMP signalling pathway and thereby inhibits platelet activation. Furthermore, 
isorhapontigenin also elevated the levels of cAMP in a concentration-dependent manner.  
Isorhapontigenin has also inhibited the Akt phosphorylation, which is an effector molecule of the 
PI3K signalling pathway (Guidetti et al., 2015) that initiates platelet activation. It is interesting to 
note that in a previous study, its analogue, resveratrol has been reported to be a non-inhibitor of 
Akt phosphorylation in platelets upon stimulation by various agonists and it had not altered the 
cAMP levels in activated platelets (Shen et al., 2007). Furthermore, the molecular interactions of 
isorhapontigenin and resveratrol with P2Y12 receptor as predicted by the in silico studies suggest 
that isorhapontigenin has greater binding affinity towards P2Y12 receptor than resveratrol. When 
compared with the interaction of clopidogrel (CLO) docked into the same site, these polyphenols 
were found to interact with different residues of the ligand binding pockets with relatively more 
hydrogen bonds. Interestingly, clopidogrel has been found to interact with Arg-256 and this was 
reported to be important for the activation of P2Y12 receptor (K. Zhang et al., 2014). However, the 
polyphenols isorhapontigenin and resveratrol have been predicted to interact with Cys-97 that  has 
been recognised as a covalent binding site for the active metabolites of P2Y12 receptor drugs 
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(Algaier et al., 2008; Ding et al., 2009). Taken together, these results suggest that isorhapontigenin 
and resveratrol act differently in platelets and these differential effects could be due to the 
structural differences where isorhapontigenin possess an additional methoxy group. 
Isorhapontigenin’s superior bioavailability than resveratrol coupled with its selective and potent 
inhibition on ADP-stimulated platelet activation suggests that isorhapontigenin may be a promising 
molecular template for the design and development of novel anti-platelet agents to prevent and 
treat thrombotic diseases. 
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Figure 1: Effect of isorhapontigenin on agonists-induced platelet aggregation. The chemical 
structures of isorhapontigenin (Ai) and resveratrol (Aii) are shown. Human platelet-rich plasma 
was incubated with a vehicle control [0.1% (v/v) DMSO] or different concentrations of 
isorhapontigenin for 5 min prior to stimulation with agonists ADP (5 μM) (B), collagen (1 μg/ml) (C), 
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CRP-XL (0.5 μg/ml)  (D) or U46619 (1 μM)  (E) and the level of platelet aggregation was monitored 
for 5 min by optical aggregometry. Representative aggregation traces of three separate 
experiments are shown. The percentage of aggregation for treated samples was calculated by 
considering the maximum aggregation obtained with the vehicle control at 5 min as 100%. The 
cumulative data shown represent mean ± S.E.M (n=3). *Indicates significant difference with 
respect to the control and #indicates significant difference with respect to the respective resveratrol 
concentrations presented in Fig 2, (*P<0.05, **P<0.01 and ***, ###P<0.001). (F) IC50 of 
isorhapontigenin on ADP-stimulated platelet aggregation: Human platelet-rich plasma was 
incubated with a vehicle control [0.1% (v/v) DMSO] or various concentrations of isorhapontigenin 
(0.19 μM–100 μM) for 5 min prior to stimulation with ADP (5 μM). The level of aggregation was 
monitored for 5 min. IC50 value was determined using GraphPad Prism. The cumulative data 
shown represent mean ± S.E.M  (n=5); ****P<0.0001. The P values shown are as calculated by 
one-way ANOVA followed by Bonferroni post-hoc test; ns: non-significant.  
Figure 2: Effect of resveratrol on agonists-induced platelet aggregation. Human platelet-rich 
plasma was incubated with a vehicle control [0.1% (v/v) DMSO] or different concentrations of 
resveratrol for 5 min prior to stimulation with agonists ADP (5 μM) (A), collagen (1 µg/ml) (B), CRP-
XL (0.5 μg/ml) (C) or U46619 (1 μM) (D) and the level of platelet aggregation was monitored for 5 
min by optical aggregometry. Representative aggregation traces of three separate experiments are 
shown. The percentage of aggregation for treated samples was calculated by considering the 
maximum aggregation obtained with the vehicle control at 5 min as 100%. The cumulative data 
shown represent mean ± S.E.M (n=3). *Indicates significant difference with respect to the control 
and #indicates significant difference with respect to the respective isorhapontigenin concentrations 
presented in Fig 1, (*P<0.05, **, ###P<0.01 and ***, ###P<0.001). The P values shown are as 
calculated by one-way ANOVA followed by Bonferroni post-hoc test.  
Figure 3: Effect of isorhapontigenin and resveratrol on agonists-induced aggregation in 
isolated platelets. Human isolated platelets were incubated with a vehicle control [0.1% (v/v) 
DMSO] or different concentrations of isorhapontigenin (A, B) or resveratrol (C, D) for 5 min prior to 
stimulation with agonists collagen (Isorhapontigenin-A; Resveratrol-C), or U46619 
(Isorhapontigenin -B; Resveratrol-D) and the level of platelet aggregation was monitored for 5 
min by optical aggregometry. Representative aggregation traces of three separate experiments are 
shown. The percentage of aggregation for treated samples was calculated by considering the 
maximum aggregation obtained with the vehicle control at 5 min as 100%. The cumulative data 
shown represent mean ± S.E.M (n=3). *Indicates significant difference with respect to the control 
(*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001). The P values shown are as calculated by one-
way ANOVA followed by Bonferroni post-hoc test.  
Figure 4: Effects of isorhapontigenin and resveratrol on inside-out signalling to integrin 
αIIbβ3 and α-granule secretion. Human platelet-rich plasma was incubated with a vehicle control 
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[0.1% (v/v) DMSO] or diverse concentrations of isorhapontigenin or resveratrol for 5 min prior to 
the addition of ADP (5 μM), CRP-XL (0.5 μg/ml) or U46619 (1 μM) and further incubated for 20 min 
at room temperature. The level of fibrinogen binding (as a marker for inside-out signalling to 
integrin αIIbβ3) to the platelet surface and the level of P-selectin exposed (as a marker for α-
granule secretion) on the platelet surface were quantified using FITC-conjugated anti-human 
fibrinogen antibodies and PECy5-conjugated anti-human P-selectin antibodies, respectively by 
flow cytometry. The bar graph shows the effects on inside-out signalling by isorhapontigenin upon 
stimulation with agonists such as ADP (A), U46619 (B) and CRP-XL (C) and by resveratrol upon 
stimulation with agonists on ADP (D), U46619 (E) and CRP-XL (F). The bar graph shows the 
effects on α-granule secretion by isorhapontigenin upon activation of platelets with agonists such 
as ADP (G), U46619 (H) and CRP-XL (I) and by resveratrol on agonists ADP (J), U46619 (K) and 
CRP-XL (L)-induced platelet activation. The extent of inhibition in treated samples was calculated 
by considering the level of fluorescence obtained with the vehicle control as 100%. Cumulative 
data represent mean ± S.E.M (n=3). The P values shown (*P<0.05) are as calculated by one-way 
ANOVA followed by Bonferroni post-hoc test.  
Figure 5: Effect of isorhapontigenin and resveratrol on dense granule secretion. Dense 
granule secretion was determined based on the amount of ATP released from platelets by lumi- 
aggregometry. Human PRP was mixed with 50 μl of luciferin-luciferase reagent for 2 min, followed 
by incubation with various concentrations of isorhapontigenin or resveratrol for a further 5 min. 
Platelets were activated with ADP (5 μM) and the level of ATP release was monitored for 5 min. 
Inhibitory effects of isorhapontigenin (A) and resveratrol (B) on dense granule secretion are 
shown. The cumulative data represent mean ± S.E.M (n=6). *Indicates significant difference with 
respect to controls and #indicates significant difference with respect to the respective resveratrol 
concentrations. The P values shown (*, #P<0.05, **P<0.01, ***P<0.01 and ***P<0.001) are as 
calculated by one-way ANOVA followed by Bonferroni post-hoc test.  
Figure 6: Effect of isorhapontigenin on platelet spreading. Human isolated platelets were 
treated with vehicle control [0.1% (v/v) DMSO] or isorhapontigenin (3.125 and 6.25 μM) for 5 min 
and were allowed to spread on fibrinogen- (100 μg/ml) coated cover-glasses (45 min). The 
platelets stained with Alexa Fluor 488 conjugated phalloidin were imaged using confocal 
microscopy. (A) Representative images of platelet spreading (n=3). (B) The graph showing the 
number of adhered and fully spread platelets. *Indicates significant difference with respect to 
control. The P values shown (***P<0.01 and ****P<0.001) are as calculated by one-way ANOVA 
followed by Bonferroni post-hoc test.  
Figure 7: Effects of isorhapontigenin on haemostasis, cytotoxicity, phosphorylation of VASP 
and Akt, and on cAMP levels. (A) Effect of isorhapontigenin on haemostasis in mice: Mice were 
anaesthetised and a vehicle control [0.1% (v/v) DMSO] or isorhapontigenin (1.85 µM or 6.25 µM) 
was injected via femoral artery. After 5 min of incubation, 3 mm of tail tip was dissected using a 
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scalpel blade and the tail tip was placed in sterile PBS. The time for cessation of bleeding was 
measured up to 20 min. Data represent ± S.E.M (n=6 mice in each group). The p value shown 
(***P<0.01) was calculated by non-parametric Kruskal-Wallis test using Graphpad Prism; ns: non-
significant. (B) The cytotoxicity of isorhapontigenin on human platelets: Human PRP was treated 
with a positive control, a vehicle control [0.1% (v/v) DMSO] or various concentrations of 
isorhapontigenin for 30 min and the amount of LDH released (a marker for cytotoxicity) was 
measured at 490 nm and 650 nm using spectrofluorimetry. The level of LDH release for 
isorhapontigenin-treated samples was calculated by considering the maximum LDH release 
obtained with the positive control as 100%. Data represent mean ± S.E.M (n=3). The statistical 
significance was calculated by one-way ANOVA. Impact of isorhapontigenin on the 
phosphorylation of VASP (C) and Akt (D): Human isolated platelets were treated with a vehicle 
control (R) or various concentrations of isorhapontigenin for 5 min before the addition of 5 μM ADP 
and further incubation for 5 min in an aggregometer at 37 °C. The level of VASP phosphorylation 
at residue S157 and Akt phosphorylation at residue S473 was detected using platelet lysates by 
immunoblot analysis. The level of 14-3-3ζ was detected as a loading control. The provided blots 
are representative of three separate experiments. The original uncropped full-length images of 
these blots are provided in SI (Fig S2). Effect of isorhapontigenin on cAMP levels (E): The total 
cellular cAMP levels in platelets pre-treated with vehicle [0.1% (v/v) DMSO] or different 
concentrations of isorhapontigenin (3.125-100 μM) and stimulated with ADP (10 µM) were 
determined using cAMP ELISA kit. Control corresponds to platelets treated with EGTA (1 mM), a 
platelet inhibitor (to achieve maximum cAMP levels). Cumulative data represent mean ± S.E.M 
(n=3). #Indicates significant difference with respect to control and *indicates significant difference 
with respect to ‘0’ concentration of isorhapontigenin. The P values shown (*P<0.05, ***P<0.01 and 
#,***P<0.001) are as calculated by one-way ANOVA followed by Bonferroni post-hoc test.  
Figure 8: Molecular interactions of isorhapontigenin and resveratrol with P2Y12 receptor. Full 
view of the P2Y12 receptor showing the binding mode of isorhapontigenin as predicted by in silico 
docking analysis (A). Superimposition of isorhapontigenin, resveratrol and clopidogrel interacting 
with the ligand binding pocket of P2Y12 receptor (B). Docking modes of isorhapontigenin (C), 
resveratrol (D) and clopidogrel (E) with P2Y12 receptor as predicted by molecular docking of 
isorhapontigenin and resveratrol into the ADP binding site of the X-ray crystallographic structure of 
P2Y12 receptor (PDB:4PXZ) using SYBYL-X 2.1 software. The 2D interactions of isorhapontigenin 
(F), resveratrol (G) and clopidogrel (H) with the key amino acid residues of P2Y12 receptor as 
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Table 1 Summary of the polar contacts and van der Waals interaction between isorhapontigenin, 
























5 (O) Gln-263 (N) 2.89 
3 (O) Thr-163 (OG1) 2.80 
3 (O) Cys-97 (O) 2.80 
 
Resveratrol 5.97 
3 (O) Thr-163 (OG1) 2.97 
112 
3 (O) Cys-97 (O) 2.77 
 5 (O) Gln-263 (NE2) 3.07  
Clopidogrel 5.95 
2 (O) Arg-256 (N) 2.73 
117 
2 (O) Tyr-105 (O) 2.31 
 
